Study of VIB7734 for the Treatment of Moderate to Severely Active SLE
(RECAST SLE Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial is testing a new drug called VIB7734 to help people with severe lupus. The drug aims to reduce the harmful activity of the immune system that causes damage in lupus patients. The study will include nearly 200 participants.
Will I have to stop taking my current medications?
The trial requires that you stay on your current SLE medications at a stable dose for a certain period before starting the study. There are specific washout periods for certain medications, so you may need to adjust your treatment plan accordingly.
Who Is on the Research Team?
MD
Principal Investigator
Amgen
Nisha Jain, MD
Principal Investigator
Horizon Therapeutics
Are You a Good Fit for This Trial?
Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive VIB7734 or placebo in a double-blind, placebo-controlled setting for the treatment of systemic lupus erythematosus
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- VIB7734
Find a Clinic Near You
Who Is Running the Clinical Trial?
Viela Bio
Lead Sponsor
Amgen
Lead Sponsor
Robert A. Bradway
Amgen
Chief Executive Officer since 2012
MBA from Harvard Business School
Paul Burton
Amgen
Chief Medical Officer since 2023
MD from University of London, PhD in Molecular and Cellular Biology from Imperial College London
Viela Bio (acquired by Horizon Therapeutics)
Lead Sponsor